The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-α) expression in acutely and chronically infected cells in vitro

Clinical and Experimental Immunology

Volumn 119, Issue 1, 2000, Pages 123-129

  La Maestra, L ^a   Zaninoni, A ^a   Marriott, J B ^a,b   Lazzarin, A ^a,c   Dalgleish, A G ^a,b   Barcellini, W ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

HIV 1 replication; Monocyte derived macrophages; Thalidomide; TNF expression; U1 cells

Indexed keywords

CC 3052; MESSENGER RNA; PHORBOL 13 ACETATE 12 MYRISTATE; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 6; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOGENESIS; MACROPHAGE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS INFECTION; VIRUS REPLICATION;

ANTI-HIV AGENTS; BASE SEQUENCE; CELL LINE; DNA PRIMERS; GENE EXPRESSION; HIV INFECTIONS; HIV-1; HUMANS; MACROPHAGES; T-LYMPHOCYTES; TETRADECANOYLPHORBOL ACETATE; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA; U937 CELLS;

EID: 0033967978     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2000.01117.x     Document Type: Article

References (33)

1. 1 Poli G, Kinter A, Justement JS, Kehrl JH, Bressler P, Stanley S, Fauci AS. Tumor necrosis factor α functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci USA 1990; 87:782-5.
2. 2 Folks TM, Clouse KA, Justement J, Rabson A, Duh E, Kehrl JH, Fauci AS. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci USA 1989; 86:2365-8.
3. 3 Folks TM, Justement J, Kinter A, Dinarello CA, Fauci AS. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 1987; 238:800-2.
4. 4 Godfried MH, Van der Poll T, Jansen J, Romijin JA, Schattenkerk JK, Endert E, Van Deventer SJ, Sauerwein HP. Soluble receptors for tumor necrosis factor: a putative marker of disease progression in HIV infection. AIDS 1993; 7:33-6.
5. 5 Aukrust P, Liabakk N, Müller F, Lien E, Espevik T, Frøland SS. Serum levels of tumor necrosis factor-α (TNF-α) and soluble TNF receptors in human immunodeficiency virus type 1 infection - correlations to clinical, immunologic, and virologic parameters. J Infect Dis 1994; 169:420-4.
6. 6 Rizzardi GP, Marriott JB, Cookson S, Lazzarin A, Dalgleish AG, Barcellini W. Tumor necrosis factor (TNF) and TNF-related molecules in HIV-1+ individuals: relationship with in vitro Th1/Th2-type response. Clin Exp Immunol 1998; 114:61-5.
7. 7 Pizzolo G, Vinante F, Morosato L et al. High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as independent of progression to AIDS. AIDS 1994; 8:741-5.
8. 8 Barcellini W, Rizzardi GP, Poli G, Tambussi G, Velati C, Meroni PL, Dalgleish AG, Lazzarin A. Cytokines and soluble receptor changes in the transition from primary to early chronic HIV type 1 infection. AIDS Res Hum Retrovir 1996; 12:325-31.
9. 9 Rizzardi GP, Barcellini W, Tambussi G, Lillo F, Malnati M, Perrin L, Lazzarin A. Plasma levels of soluble CD30, tumor necrosis factor (TNF)-α and TNF receptors during primary HIV-1 infection: correlation with HIV-1 RNA and the clinical outcome. AIDS 1996; 10:F45-F50.
10. 10 Fazely F, Dezube BJ, Allen-Ryan J, Pardee AB, Ruprechr RM. Pentoxifylline (Trental) decreases the replication of the human immunodeficiency virus type 1 in human peripheral blood mononuclear cells and in cultured T cells. Blood 1991 ; 77:1653-6.
11. 11 Luke DR, McCreedy BJ, Sarnoski TP et al. Phase I/II study of pentoxifylline with zidovudine on HIV-1 growth in AIDS patients. Int J Clin Pharmacol Ther Toxicol 1993; 31:343-50.
12. 12 Dezube BJ. Pentoxifylline for the treatment of infection with human immunodeficiency virus. Clin Infect Dis 1994; 18:285-7.
13. 13 Sampaio EP, Sarno EN, Gallily R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor-α production by stimulated human monocytes. J Exp Med 1991; 173:699-703.
14. 14 Moreira AL, Sampaio EP, Zmuidzinas A, Fridt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor-α by enhancing mRNA degradation. J Exp Med 1993; 177:1675-80.
15. 15 Sampaio EP, Kaplan G, Miranda A, Nery JAC, Miguel CP, Viana SM, Sarno EN. The influence of thalidomide on the clinical and immunological manifestation of erythema nodous leprosum. J Infect Dis 1993; 168:408-14.
16. 16 Makonkawkeyoon S, Limson-Probe RNR, Moreira AL, Schauf V, Kaplan G. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993; 90:5974-8.
17. 17 Moreira AL, Corral LGYeW, Johnson B, Stirling D, Muller GW, Freedman VH, Kaplan G. Thalidomide and thalidomide analogs reduce HIV type-1 replication in human macrophages in vitro. AIDS Res Hum Retrovir 1997; 13:857-63.
18. 18 Klausner JD, Makonkawkeyoon S, Akarasewi P et al. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol; 1996; 11:247-57.
19. 19 Marriott JB, Cookson S, Carlin E et al. A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: clinical tolerance and effect on activation markers and cytokines. AIDS Res Hum Retrovir 1997; 13:1625-31.
20. 20 Marriott JB, Websty M, Cookson S et al. CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production. J Immunol 1998; 161:4236-43.
21. 21 Barcellini W, Rizzardi GP, Marriott JB, Fain C, Shattock RJ, Meroni PL, Poli G, Dalgleish AG. Interleukin-10-induced HIV-1 expression is mediated by induction of both membrane-bound-tumor necrosis factor (TNF)-α and TNF receptor type 1 in a promonocytic cell line. AIDS 1996; 10:835-42.
22. 22 Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63.
23. 23 Poli G, Fauci AS. Cytokine modulation of HIV expression. Seminars Immunol 1993; 5:165-73.
24. 24 Poli G, Bressler P, Kinter A et al. Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor α by transcriptional and post-transcriptional mechanisms. J Exp Med 1990; 172:151-8.
25. 25 Pantaleo G, Demarest JF, Soudeyns H et al. Major expansion of CD8+ T cells with a predominant Vβ usage during the primary immune response to HIV. Nature 1994; 370:463-7.
26. 26 Fauci AS. Host factors and the pathogenesis of HIV-induced disease. Nature 1996; 384:529-34.
27. 27 Mellors JW, Munoz A, Giorgi JV et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Int Med 1997; 126:946-54.
28. 28 Pantaleo G, Demarest JF, Schacker T et al. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci USA 1997; 94:254-8.
29. 29 Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath MJ. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1. N Engl J Med 1997; 337:1267-74.
30. 30 Kahn JO, Walker BD. Acute human immunodeficiency virus type I infection. N Engl J Med 1998; 339:33-9.
31. 31 Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 1998; 95:8869-73.
32. 32 Pantaleo G, Cohen OJ, Schacker T et al. Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: implications for antiviral therapy. Nature Med 1998; 4:341-5.
33. 33 Manogue KR, Van Deventer SJH, Cerami A. Tumor necrosis factor-α or cachectin. In: Tompson A, ed. The cytokine handbook. London: Academic Press, 1991:241-56.